Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: OPC-6535

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Anti-inflammatories; Anti-ischaemics; Carboxylic acids; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Crohn's disease; Heart failure; Reperfusion injury; Ulcerative colitis

Most Recent Events

  • 09 Sep 2015 Phase-II development is ongoing for Chronic obstructive pulmonary disease in Japan, US and Asia
  • 07 Aug 2015 Otsuka terminates phase II trial in Chronic obstructive pulmonary disorders in USA (NCT00874497)
  • 01 Apr 2014 Otsuka Pharmaceutical completes a phase II in Chronic obstructive pulmonary disease in Japan, China, and South Korea (NCT00917150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top